Chronic lymphocytic leukemia patients with deletion 11q have a short time to requirement of first-line therapy, but long overall survival: results of a population-based cohort in British Columbia, Canada

Conclusions Although median TFS of 11q- patients in this cohort is short at 2.5 years, OS remains long at 14.7 years, even when the majority of patients received initial treatment without alkylators. Teaser This study documents the clinical course of 67 with high-risk CLL patients with 11q- deletion, from a Provincial CLL database. Aklylator-containing chemotherapies are thought to required to overcome the adverse prognosis associated with 11q-. However, most 11q- patients did not receive alkylators first line and had a median survival of 14.7 years, comparable to the rest of the cohort.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research